1. Search Result
Search Result
Results for "

osteoclasts

" in MedChemExpress (MCE) Product Catalog:

108

Inhibitors & Agonists

10

Peptides

1

Inhibitory Antibodies

41

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N2465

    Others Inflammation/Immunology
    Methylsticin is a kavalactone isolated from the Piper methysticum . Methylsticin exhibit osteoclast formation inhibitory activity .
    Methylsticin
  • HY-122082

    Others Inflammation/Immunology
    Methopterin inhibits osteoclasts proliferation. Methopterin inhibits the activation and bone resorption function of osteoclasts, and induced osteoclasts apoptosis .
    Methopterin
  • HY-122082R

    Others Inflammation/Immunology
    Methopterin (Standard) is the analytical standard of Methopterin. This product is intended for research and analytical applications. Methopterin inhibits osteoclasts proliferation. Methopterin inhibits the activation and bone resorption function of osteoclasts, and induced osteoclasts apoptosis .
    Methopterin (Standard)
  • HY-155977

    Others Others
    Anti-osteoporosis agent-5 (compound 189) is a potent inhibitor of the formation of osteoclasts .
    Anti-osteoporosis agent-5
  • HY-N8215

    Others Metabolic Disease
    Achyranthoside C is a saponin from Achyranthes bidentata. The derivative of Achyranthoside C has inhibitory activity on osteoclast formation .
    Achyranthoside C
  • HY-N2465R

    Others Inflammation/Immunology
    Methylsticin (Standard) is the analytical standard of Methylsticin. This product is intended for research and analytical applications. Methylsticin is a kavalactone isolated from the Piper methysticum . Methylsticin exhibit osteoclast formation inhibitory activity .
    Methylsticin (Standard)
  • HY-P10078

    Thyroid Hormone Receptor Inflammation/Immunology
    pTH (39-84) (human) is a parathyroid hormone (PTH) C-terminal fragment. pTH (39-84) (human) stimulates osteoclast formation .
    pTH (39-84) (human)
  • HY-168090

    p38 MAPK NF-κB RANKL/RANK Endocrinology
    Anti-osteoporosis agent-11 (compound 3k) is an anti-osteoporosis compound targeting osteoclasts. Anti-osteoporosis agent-11 has the most significant inhibitory effect on osteoclast differentiation, with an IC50 value of 0.36 μM. In addition, Anti-osteoporosis agent-11 inhibits osteoclast formation, bone resorption, and the expression of osteoclast-specific genes by blocking rankl-induced mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways .
    Anti-osteoporosis agent-11
  • HY-155985

    Others Metabolic Disease
    Anti-osteoporosis agent-6 (compound 174) is an anti-osteoporosis agent. Anti-osteoporosis agent-6 has 14.11% inhibition rate against osteoclast formation at 10 μM .
    Anti-osteoporosis agent-6
  • HY-149472

    NF-κB PI3K Inflammation/Immunology
    Anti-osteoporosis agent-4 (Compound 11h) inhibits differentiation of primary osteoclasts. Anti-osteoporosis agent-4 attenuates RANKL-induced osteoclastogenesis. Anti-osteoporosis agent-4 inhibits osteoclast formation with an IC50 value of 358.29 nM. Anti-osteoporosis agent-4 inhibits PI3K/AKT and IκBα/NF-κB signaling pathway activation .
    Anti-osteoporosis agent-4
  • HY-N7613

    Others Others
    6''-O-Acetylsaikosaponin A, an acetyl saikosaponin isolated from the roots of Bupleurum chinense, shows some osteoclast-inhibiting activities .
    6''-O-Acetylsaikosaponin A
  • HY-10294

    SB-462795

    Cathepsin Metabolic Disease Cancer
    Relacatib (SB-462795) is a novel, potent, and orally active inhibitor of human cathepsins K, L, and V with Ki values of 41 pM, 68 pM, and 53 pM, respectively. Relacatib inhibits endogenous cathepsin K in situ in human osteoclasts and human osteoclast-mediated bone resorption with IC50 values of 45 nM and 70 nM, respectively. Relacatib inhibits bone resorption in vitro in human tissue as well as in cynomolgus monkeys in vivo .
    Relacatib
  • HY-N1098

    HIF/HIF Prolyl-Hydroxylase Inflammation/Immunology
    Velutin is an aglycone extracted from Flammulina velutipes, with inhibitory activity against melanin biosynthesis. Velutin reduces osteoclast differentiation and down-regulates HIF-1α through the NF-κB pathway .
    Velutin
  • HY-169070

    PPAR Others
    Anti-osteoporosis agent-10 is an osteoporosis inhibitor. Anti-osteoporosis agent-10 can suppress the generation of osteoclasts, with an IC50 of 0.042 μM. Anti-osteoporosis agent-10 also has antagonistic activity on PPARγ, with an EC50 value of 0.75 μM .
    Anti-osteoporosis agent-10
  • HY-13777
    Zoledronic Acid
    10+ Cited Publications

    Zoledronate; CGP 42446; CGP42446A; ZOL 446

    Apoptosis Autophagy Bacterial Metabolic Disease Cancer
    Zoledronic Acid (Zoledronate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic Acid inhibits the differentiation and apoptosis of osteoclasts. Zoledronic Acid also has anti-cancer effects .
    Zoledronic Acid
  • HY-13777A
    Zoledronic acid monohydrate
    10+ Cited Publications

    Zoledronate monohydrate; CGP 42446 monohydrate; CGP42446A monohydrate; ZOL 446 monohydrate

    Apoptosis Autophagy Bacterial Metabolic Disease Cancer
    Zoledronic acid monohydrate (Zoledronate monohydrate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic acid monohydrate inhibits the differentiation and apoptosis of osteoclasts. Zoledronic acid monohydrate also has anti-cancer effects .
    Zoledronic acid monohydrate
  • HY-N12836

    Others Metabolic Disease
    Peniditerpenoid A is a di-seco-indole diterpenoid. Peniditerpenoid A decreases the expression of p-IkBαby RANKL induced. Peniditerpenoid A inhibits RANKL induced osteoclast differentiation. Peniditerpenoid A has the potential for the research of osteoporosis .
    Peniditerpenoid A
  • HY-124081

    Apoptosis Metabolic Disease
    N-Oleoyl-L-Serine is an endogenous amide of long-chain fatty acids with ethanolamine (N-acyl amides). N-Oleoyl-L-Serine is a lipid regulator of bone remodeling and stimulates osteoclast apoptosis. N-Oleoyl-L-Serine can be used for antiosteoporotic drug discovery development .
    N-Oleoyl-L-serine
  • HY-N9359

    Apoptosis Cardiovascular Disease
    Toddaculin is a natural coumarin that can induce differentiation and apoptosis in leukemic cells. Toddaculin suppresses excess osteoclast activity and enhances osteoblast differentiation and mineralization. Toddaculin also exhibits anti-inflammatory activity .
    Toddaculin
  • HY-13777R

    Apoptosis Autophagy Bacterial Metabolic Disease Cancer
    Zoledronic Acid (Standard) is the analytical standard of Zoledronic Acid. This product is intended for research and analytical applications. Zoledronic Acid (Zoledronate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic Acid inhibits the differentiation and apoptosis of osteoclasts. Zoledronic Acid also has anti-cancer effects .
    Zoledronic Acid (Standard)
  • HY-13777AR

    Apoptosis Autophagy Bacterial Metabolic Disease Cancer
    Zoledronic acid (monohydrate) (Standard) is the analytical standard of Zoledronic acid (monohydrate). This product is intended for research and analytical applications. Zoledronic acid monohydrate (Zoledronate monohydrate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic acid monohydrate inhibits the differentiation and apoptosis of osteoclasts. Zoledronic acid monohydrate also has anti-cancer effects .
    Zoledronic acid monohydrate (Standard)
  • HY-13777S

    Zoledronate-d5; CGP 42446-d5; CGP42446A-d5; ZOL 446-d5

    Bacterial Apoptosis Autophagy Isotope-Labeled Compounds Metabolic Disease Cancer
    Zoledronic acid-d5 is deuterated labeled Zoledronic Acid (HY-13777). Zoledronic Acid (Zoledronate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic Acid inhibits the differentiation and apoptosis of osteoclasts. Zoledronic Acid also has anti-cancer effects .
    Zoledronic acid-d5
  • HY-N6624

    Bacterial Inflammation/Immunology
    Skullcapflavone II, a flavonoid derived from Scutellaria baicalensis, has anti-inflammatory, anti-microbial activities. Skullcapflavone II regulates osteoclast differentiation, survival, and function. Skullcapflavone II exerts potent antimicrobial activity against M. aurum and M. bovis BCG .
    Skullcapflavone II
  • HY-N0656
    Usnic acid
    1 Publications Verification

    Bacterial Infection Cancer
    Usnic acid, a lichen-derived secondary metabolite, has a unique dibenzofuran skeleton. Usnic acid has excellent anticancer and antimicrobial properties. Usnic acid significantly inhibits RANKL-mediated osteoclast formation and function by reducing the transcriptional and translational expression of NFATc1 .
    Usnic acid
  • HY-N2528

    Bacterial Infection Cancer
    Usnic acid sodium, a lichen-derived secondary metabolite, has a unique dibenzofuran skeleton. Usnic acid sodium has excellent anticancer and antimicrobial properties. Usnic acid sodium significantly inhibits RANKL-mediated osteoclast formation and function by reducing the transcriptional and translational expression of NFATc1 .
    Usnic acid sodium
  • HY-129337

    Antibiotic Fungal Apoptosis Infection Cancer
    Reveromycin A, a benzoquinoid antibiotic isolated from the genus Streptomyces, is a selective inhibitor of protein synthesis in eukaryotic cells. Reveromycin A inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Reveromycin A has antiproliferative activity against tumor cell lines and antifungal activity .
    Reveromycin A
  • HY-W438351

    RANKL/RANK Metabolic Disease
    1,3-Dibenzyl-5-fluorouracil is a chemical inhibitor of osteoclastogenesis. 1,3-Dibenzyl-5-fluorouracil inhibits the expression of osteoclast markers by downregulating the receptor activator of NF-κB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) signaling pathways. 1,3-Dibenzyl-5-fluorouracil can be used in the study of metabolic bone diseases .
    1,3-Dibenzyl-5-fluorouracil
  • HY-W012980

    Endogenous Metabolite AMPK PKA Metabolic Disease
    Isovaleric acid is an oral active short-chain fatty acid that inhibits osteoclast differentiation by stimulating AMPK phosphorylation and promotes colonic smooth muscle relaxation by activating the cAMP/PKA pathway. Isovaleric acid can be used in research on skeletal diseases (such as osteoporosis) and intestinal disorders .
    Isovaleric acid
  • HY-13777B

    Zoledronate disodium tetrahydrate; CGP 42446 disodium tetrahydrate; CGP42446A disodium tetrahydrate; ZOL 446 disodium tetrahydrate

    Apoptosis Autophagy Bacterial Metabolic Disease Cancer
    Zoledronic Acid (Zoledronate) disodium tetrahydrate is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic Acid disodium tetrahydrate inhibits the differentiation and apoptosis of osteoclasts. Zoledronic Acid disodium tetrahydrate also has anti-cancer effects .
    Zoledronic acid disodium tetrahydrate
  • HY-126825

    Others Metabolic Disease
    NE21650 potently inhibits farnesyl diphosphate (FPP) synthase. NE21650 is a weak inhibitor of isopentenyl diphosphate (IPP) isomerase. NE21650 is a potent inhibitor of protein prenylation in osteoclasts and macrophages and bone resorption in vitro .
    NE21650
  • HY-P4373A

    Cathepsin MMP Inflammation/Immunology
    Hepcidin-1 (mouse) TFA is an endogenous peptide hormone involved in the regulation of iron homeostasis. Hepcidin-1 (mouse) TFA upregulates mRNA levels of TRAP, cathepsin K, and MMP-9 and increases TRAP-5b protein secretion. Hepcidin-1 (mouse) TFA downregulates the level of FPN1 protein and increases intracellular iron. Hepcidin-1 (mouse) TFA facilitates osteoclast differentiation .
    Hepcidin-1 (mouse) (TFA)
  • HY-W012980R

    Endogenous Metabolite AMPK PKA Metabolic Disease
    Isovaleric acid (Standard) is the analytical standard of Isovaleric acid. This product is intended for research and analytical applications. Isovaleric acid is an oral active short-chain fatty acid that inhibits osteoclast differentiation by stimulating AMPK phosphorylation and promotes colonic smooth muscle relaxation by activating the cAMP/PKA pathway. Isovaleric acid can be used in research on skeletal diseases (such as osteoporosis) and intestinal disorders .
    Isovaleric acid (Standard)
  • HY-N9199

    Others Others
    6β,19-Dihydroxyurs-12-en-3-oxo-28-oic acid (Compound 14) is an osteoclast inhibitor with anti-osteoclastogenic activity. 6β,19-Dihydroxyurs-12-en-3-oxo-28-oic acid can be obtained from Eriobotrya japonica leaves. 6β,19-Dihydroxyurs-12-en-3-oxo-28-oic acid can be used in osteoporosis research .
    6β,19-Dihydroxyurs-12-en-3-oxo-28-oic acid
  • HY-122019

    Others Others
    ABD56 is a compound that induces osteoclast apoptosis and has the activity of inhibiting osteoclast formation and inducing apoptosis. ABD56 can inhibit osteoclast formation and induce apoptosis, and its mechanism is related to the inhibition of NFκB and ERK pathways.
    ABD56
  • HY-147369
    NFATc1-IN-1
    1 Publications Verification

    Nuclear Factor of activated T Cells (NFAT) Others
    NFATc1-IN-1 (compound A04) is a potent inhibitor of RANKL-induced osteoclast formation, with an IC50 of 1.57 μM. NFATc1-IN-1 shows anti-osteoclastogenic effects through reducing the RANKL-induced nuclear translocation of NFATc1. NFATc1-IN-1 can be used for osteoclastic diseases research .
    NFATc1-IN-1
  • HY-113933

    Others Others
    NE11808 is a potent antiresorptive bisphosphonate that inhibits osteoclast prenylation and effectively inhibits protein prenylation in osteoclasts and suppresses labeling of dye-front end compounds.
    NE11808
  • HY-123370

    Proton Pump Metabolic Disease Cancer
    FR-167356 is a potent, orally active and selective vacuolar ATPase inhibitor with IC50 values of 170, 220, 370, and 1200 nM for osteoclast plasma membranes, macrophage microsomes, renal brush border membranes, and liver lysosomal membranes, respectively. FR-167356 inhibits bone resorption and ovariectomy-induced bone loss .
    FR-167356
  • HY-B0119
    Risedronic acid sodium
    1 Publications Verification

    Risedronate sodium

    Parasite Others
    Risedronic acid (Risedronate) sodium is a bisphosphonate that inhibits osteoclast-mediated bone resorption.
    Risedronic acid sodium
  • HY-N0499
    Cyanidin Chloride
    3 Publications Verification

    IdB 1027

    RANKL/RANK Cancer
    Cyanidin Chloride (IdB 1027), a subclass of anthocyanin, displays antioxidant and anti-carcinogenesis properties. Cyanidin Chloride (IdB 1027) inhibits osteoclast formation, hydroxyapatite resorption, and receptor activator of NF-κB ligand (RANKL)-induced osteoclast marker gene expression .
    Cyanidin Chloride
  • HY-B0148
    Risedronic acid
    1 Publications Verification

    Risedronate

    Parasite Cancer
    Risedronic acid (Risedronate ) is a pyridinyl biphosphonate which inhibits osteoclast-mediated bone resorption.
    Risedronic acid
  • HY-125064

    Src Cancer
    AP22408 is a nonpeptide inhibitor against Src SH2 with an IC50 value of 0.3 μM. AP22408 inhibits rabbit osteoclast-mediated resorption of dentine, exhibits bone-targeting properties based on a hydroxyapatite adsorption assay and demonstrates in vivo antiresorptive activity in a parathyroid hormone-induced rat model. AP22408 is proming for rasearch of osteoporosis and other bone-related diseases such as Paget’s disease, osteolytic bone metastasis and hypercalcemia associated with malignancy .
    AP22408
  • HY-N0805A

    Others Metabolic Disease
    Alisol B is a potentially novel therapeutic compound for bone disorders by targeting the differentiation of osteoclasts as well as their functions.
    Alisol B
  • HY-N0499R

    RANKL/RANK Cancer
    Cyanidin (Chloride) (Standard) is the analytical standard of Cyanidin (Chloride). This product is intended for research and analytical applications. Cyanidin Chloride (IdB 1027), a subclass of anthocyanin, displays antioxidant and anti-carcinogenesis properties. Cyanidin Chloride (IdB 1027) inhibits osteoclast formation, hydroxyapatite resorption, and receptor activator of NF-κB ligand (RANKL)-induced osteoclast marker gene expression .
    Cyanidin Chloride (Standard)
  • HY-W008634

    Toll-like Receptor (TLR) Cancer
    Bropirimine is a synthetic agonist for toll-like receptor 7 (TLR7). Bropirimine inhibits differentiation of osteoclast precursor cells into osteoclasts via TLR7-mediated production of IFN-β. Bropirimine is an orally active immunomodulator that has demonstrated anticancer activity in transitional cell carcinoma in situ (CIS) in both the bladder and upper urinary tract .
    Bropirimine
  • HY-115720

    Others Inflammation/Immunology
    Betulinic acid derivative-1 exhibits distinguished activities on inhibiting osteoclast (OC) differentiation with an IC50 value of 1.86 μM.
    Betulinic acid derivative-1
  • HY-49069

    Others Others
    Anti-osteoporosis agent-7 (Compound 133) is a potential anti-osteoporosis agent showing high inhibition of osteoclast formation.
    Anti-osteoporosis agent-7
  • HY-N11494

    NF-κB Others
    Dauricumine is a chlorinated alkaloid that inhibits NF-κB ligand-induced differentiation of mouse bone marrow-derived macrophages into multinucleated osteoclasts .
    Dauricumine
  • HY-118668

    Others Others
    ABD-350 is an antiresorptive agent that inhibits osteoclast activity without affecting osteoblast activity and preventing ovariectomy-induced bone loss. ABD-350 inhibits NF-κB ligand-induced inhibitor of NF-κB phosphorylation, leading to osteoclast apoptosis, but has no inhibitory effect on osteoblast function, effectively preventing bone loss in ovariectomized mice, and does not inhibit parathyroid hormone-induced bone formation.
    ABD-350
  • HY-163847

    Others Inflammation/Immunology
    Anti-osteoporosis agent-9 (compound 5b) 是一种 N-环丙基-4-((磺酰哌嗪-1-基)甲基)苯酰胺衍生物,显示出抗破骨细胞活性。
    Anti-osteoporosis agent-9
  • HY-B0148S

    Isotope-Labeled Compounds Others
    Risedronic Acid-d4 is the deuterium labeled Risedronic acid. Risedronic acid (Risedronate) is a pyridinyl biphosphonate which inhibits osteoclast-mediated bone resorption[1][2].
    Risedronic Acid-d4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: